Calgent Biotech to Present New Preclinical Data on CAL010 at ObesityWeek® 2026

Calgent Biotech to Present New Preclinical Data on CAL010 at ObesityWeek® 2026

•CAL010 promoted selective fat loss and enhanced incretin therapy efficacy in Diet-Induced Obesity (DIO) mouse models.
•Preclinical data support CAL010’s development as a differentiated obesity therapy.

TAIPEI, Taiwan – November 13, 2026 – Calgent Biotechnology Co., Ltd. (“Calgent” or “the Company”), a Taiwan-based biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs, today announced that it will present new preclinical findings from its investigational obesity candidate, CAL010, at ObesityWeek® 2026, taking place November 14–17 in Washington, D.C., hosted by The Obesity Society (TOS).

The poster presentation, entitled “CAL010 Drives Selective Fat Loss and Potentiates Incretin-Based Therapies in Diet-Induced Obesity (DIO) Mice,” will be presented in the Personalized, Digital & Population-Based Obesity Care session within Track 1: Metabolism and Integrative Physiology. The presentation is scheduled for November 15 at 2:30 p.m. (Washington, D.C. local time).

The research highlights the therapeutic potential of CAL010 in promoting selective fat loss and its ability to potentiate the effects of incretin-based therapies in diet-induced obesity (DIO) mouse models. These findings support further investigation of CAL010 as a potential differentiated therapeutic approach for obesity, particularly in combination with established incretin-based treatments.

“We are honored to share our latest preclinical findings on CAL010 at ObesityWeek 2026,” said Hui-Wen Huang, Chief Executive Officer of Calgent. “Our research highlights the potential of CAL010. We look forward to engaging with leading experts in the field, and exploring opportunities for collaboration and strategic partnerships to further advance CAL010’s development.”

Poster Presentation Details
•Title: CAL010 Drives Selective Fat Loss and Potentiates Incretin-Based Therapies in Diet-Induced Obesity (DIO) Mice
•Date: November 15, 2026
•Time: 2:30 p.m. local time
•Session: Personalized, Digital & Population-Based Obesity Care (Track 1)
•Poster Number: 562
•Abstract URL: https://planion.events/e/tos/ow2026/abstracts/2110673/

About Calgent
Headquartered in Taiwan, Calgent is an innovative biopharmaceutical company dedicated to developing novel therapeutics to address unmet medical needs. Founded in 2019, the company focuses on advancing differentiated drug candidates across oncology, immunology and inflammation, and metabolic diseases. Calgent has established integrated drug development capabilities spanning translational medicine, pharmacology and toxicology validation, formulation development, and clinical development. Through innovation, strategic partnerships, and a globally oriented development strategy, Calgent aims to advance promising therapeutic candidates toward clinical application and bring innovative treatment options to patients worldwide.

About CAL010
CAL010 is a first-in-class fat reduction investigational therapeutic candidate that selectively kills adipocytes and dose-dependently reduces target adipose tissue mass without inflammatory side effects. CAL010 is also being developed for systemic reduction adipose mass with preservation of muscle mass.

Forward-Looking Statements
This press release contains forward-looking statements regarding Calgent’s business, research and development programs, product candidates, future plans, and anticipated milestones. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including risks associated with drug development, clinical and regulatory outcomes, financing needs, and other factors beyond the Company’s control. Calgent undertakes no obligation to update any forward-looking statements except as required by applicable law.

Media and Investor Contact
Calgent Biotech 
Email: info@calgent.com 
Website: www.calgent.com



Scroll to Top